Other · developed by Korro Bio
KRRO-121 is a subcutaneously injected agent studied in urea cycle disorders, including ornithine transcarbamylase deficiency, arginase 1 deficiency, and argininosuccinate lyase deficiency.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07773246 | Phase 1/2 | Urea Cycle Disorders, Inborn | Recruiting | KRRO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Arginase 1 DeficiencyArgininosuccinate Lyase DeficiencyArgininosuccinate SynthaseCarbamylphosphate Synthetase ICitrin DeficiencyN-acetyl Glutamate - SynthetaseNAGS DeficiencyOrnithine Transcarbamylase (OTC) DeficiencyOrnithine Transporter Mitochondrial 1Urea Cycle DisordersUrea Cycle Disorders, Inborn
Updated Oct 25, 2026. Something wrong or missing? Report it on the KRRO page.
See KRRO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
KRRO catalysts and pipeline →